RxDoctor Payments Data

Sunaina Likhari, MD

Dermatology · Sugar Land, TXNPI 1033430087

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.5% of the total across 164 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for dermatology clinicians in TX, where the typical reported total is $4,085.

$3,511in general payments, 2019–2025

Across 164 payments — averaging $21.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$763
  • AbbVie$436
  • Lilly USA, LLC$404
  • Sanofi$347
  • Amgen$260
  • Pfizer$173
  • plus $1K from 23 others
$46,992in research payments, 2019–2025

Across 13 payments — averaging $3614.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$24K
  • Incyte Corporation$11K
  • Sanofi US Services Inc.$11K

What the payments were for

  • Food & beverage$3,494100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,511 in reported general payments places this provider in the 45th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas →

Medicare billing

Part B allowed, 2024
$64,053
Medicare patients
228
Services billed
812

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clobetasol Propionate43$1,211
Ketoconazole67$966
Fluorouracil13$714
Metronidazole15$656
Triamcinolone Acetonide68$594
Clindamycin Phosphate21$565
Fluocinolone Acetonide12$416
Hydroxychloroquine Sulfate13$326
Mupirocin24$148
Hydrocortisone33$133

Paid to pharmacies, not to this prescriber.

Other dermatology in Sugar Land

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →